

ADVANCED MATERIALS



PHARMACOVIGILANCE
MADE EASY

PHARMACOVIGILANCE
MADE EASY

ADVANCED PHARMACOVIGILANCE MATERIALS

PV MATERIAL SOLID

<https://allaboutpharmacovigilance.org/pharmacovigilance-guidance-material/icsr-processing-aggregate-reporting-and-signal-management/>

LISTEDNESS/EXPECTEDNESS/LABELLED/UNLABELLED

<https://allaboutpharmacovigilance.org/18-i-listedness-expectedness-assessment-introduction/>

<https://allaboutpharmacovigilance.org/18-ii-listedness-expectedness-assessment-reference-safety-information-documents/>

<https://allaboutpharmacovigilance.org/19-1-guidelines-and-examples-of-expectedness-assessment/>

CAUSALITY ASSESSMENT

<https://allaboutpharmacovigilance.org/19-causality-assessment/>

<https://allaboutpharmacovigilance.org/20-scale-for-causality-assessment/>

NARRATIVE WRITING

<https://allaboutpharmacovigilance.org/21-narrative-writing/>

ICSR/CASE FOLLOW-UP – LIST OF ITEMS THAT MUST BE INCLUDED

<https://allaboutpharmacovigilance.org/22-case-follow-up/>

AGGREGATE REPORTING (PADER, PBRER)/ IND ANNUAL REPORT

<https://allaboutpharmacovigilance.org/23-aggregate-reporting-introduction/>

<https://allaboutpharmacovigilance.org/24-aggregate-reporting-ind-annual-reports/>

<https://allaboutpharmacovigilance.org/30-periodic-adverse-drug-experience-report-pader-paer/>

CLINICAL STUDY REPORT (CSR) – MUST BE SUBMITTED TO FDA WITHIN 1 YEAR OF THE END OF STUDY IN ADULTS AND 6 MONTHS IN CHILDREN

<https://allaboutpharmacovigilance.org/25-csr-reports/>

NDA/ANDA ANNUAL REPORT

<https://allaboutpharmacovigilance.org/26-nda-and-anda-annual-reports/>

DEVELOPMENT SAFETY UPDATE REPORT

<https://allaboutpharmacovigilance.org/27-development-safety-update-report-dsur/>

PERIODIC SAFETY UPDATE REPORT (PSUR) OR PERIODIC BENEFIT RISK EVALUATION REPORT, PERIODIC ADVERSE DRUG EXPERIENCE REPORT

<https://allaboutpharmacovigilance.org/28-periodic-safety-update-reports-psurs-periodic-benefit-risk-evaluation-reports-pbrer-and-periodic-adverse-drug-experience-report-pader-introduction/>

<https://allaboutpharmacovigilance.org/29-periodic-safety-update-reports-psurs-periodic-benefit-risk-evaluation-reports-pbrer/>

SIGNAL MANAGEMENT

SIGNALS:

<https://allaboutpharmacovigilance.org/31-signal-introduction/>

SIGNAL DETECTION:

<https://allaboutpharmacovigilance.org/32-signal-management-signal-detection/>

SIGNAL VALIDATION:

<https://allaboutpharmacovigilance.org/33-signal-validation/>

SIGNAL PRIORITIZATION

<https://allaboutpharmacovigilance.org/34-signal-prioritisation/>

SIGNAL ASSESSMENT – EVALUATION OF RISK

<https://allaboutpharmacovigilance.org/35-signal-assessment-evaluation-of-risk/>

RECOMMENDATION OF ACTION AND INFORMATION EXCHANGE

<https://allaboutpharmacovigilance.org/36-recommendation-for-action-and-exchange-of-information/>

BENEFIT-RISK ASSESSMENT

<https://allaboutpharmacovigilance.org/introduction-to-benefit-risk-assessment/>

<https://allaboutpharmacovigilance.org/38-risk-benefit-evaluation-process-overview/>

RISK MANAGEMENT PLAN

<https://allaboutpharmacovigilance.org/40-medicine-safety-plans-rmp-and-rems/>

SAFETY SIGNAL DETECTION AND DATA MINING

<https://allaboutpharmacovigilance.org/41-safety-signal-detection-methods-data-mining-approach/>

PROPORTIONAL REPORTING RATIO

<https://allaboutpharmacovigilance.org/42-data-mining-proportional-reporting-ratio/>

REPORTING ODDS RATIO

<https://allaboutpharmacovigilance.org/43-reporting-odds-ratio-ror/>

RELATIVE REPORTING RATIO

<https://allaboutpharmacovigilance.org/44-relative-reporting-ratio-rrr/>

CHI SQUARE

<https://allaboutpharmacovigilance.org/45-chi-square-%CF%872/>

INFORMATION COMPONENT

<https://allaboutpharmacovigilance.org/46-the-information-component/>

BAYESIAN CONFIDENCE PROPAGATION NEURAL NETWORK

<https://allaboutpharmacovigilance.org/47-bayesian-confidence-propagation-neural-network/>

MULTI-ITEM GAMMA SHRINKER

<https://allaboutpharmacovigilance.org/48-multi-item-gamma-poisson-shrinker-mgps-algorithm/>

TRADITIONAL METHODS OF SIGNAL DETECTION

<https://allaboutpharmacovigilance.org/traditional-methods-of-signal-detection/>

ADVERSE EVENT OF SPECIAL INTEREST (AESI)

<https://allaboutpharmacovigilance.org/adverse-event-of-special-interest-aesi/>